Warten auf den Duke Report
15.12.09 16:49
#1
Menne
Warten auf den Duke Report
Trillenium Medical Imaging (TMI) provides functional imaging systems through the use of infrared detection. This technology blends proprietary software with a highly durable and fully calibrated thermal detection device to record variances in body temperature.
Infrared thermal imaging is a non-invasive, imaging procedure involving the detection and recording of skin thermal patterns, providing visual and quantitative documentation. The interpretation of these temperatures and thermal patterns can play an important part in the development of a diagnosis. Because Infrared Imaging can display the variations in skin temperature patterns and these variations are known pathways of information, it can be invaluable as an integral part of the physical examination.
Such technology has been successfully tested and is currently in use to assist in diagnosis, treatment monitoring and case management of many health issues. These include, but not limited to: vascular, neurological and muscular-skeletal disorders such as breast cancer, diabetes, and unresolved pain issues related to myofascial complaints, muscle injury or neurological dysfunction.
TMI is THE source for non-invasive Imaging devices for the treating professional who requires a physiological imaging test for diagnosis or case management.
Infrared thermal imaging is a non-invasive, imaging procedure involving the detection and recording of skin thermal patterns, providing visual and quantitative documentation. The interpretation of these temperatures and thermal patterns can play an important part in the development of a diagnosis. Because Infrared Imaging can display the variations in skin temperature patterns and these variations are known pathways of information, it can be invaluable as an integral part of the physical examination.
Such technology has been successfully tested and is currently in use to assist in diagnosis, treatment monitoring and case management of many health issues. These include, but not limited to: vascular, neurological and muscular-skeletal disorders such as breast cancer, diabetes, and unresolved pain issues related to myofascial complaints, muscle injury or neurological dysfunction.
TMI is THE source for non-invasive Imaging devices for the treating professional who requires a physiological imaging test for diagnosis or case management.
66 Postings ausgeblendet.
23.06.10 08:23
#71
Menne
Form 10-Q for WELLSTAR INTERNATIONAL, INC
21.06.2010
http://biz.yahoo.com/e/100621/wlsi.ob10-q.html
21-Jun-2010
Quarterly Report
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Special Note on Forward-Looking Statements
Certain statements in Management's Discussion and Analysis ("MD&A"), other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements". These forward-looking statements generally are identified by the words "believe," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. These statements are subject to a number of risks, uncertainties and developments beyond our control or foresight including changes in the trends of the mobile computing industry, formation of competitors, changes in governmental regulation or taxation, changes in our personnel and other such factors. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers should carefully review the risk factors and related notes included in the Company's Form 10-K and other SEC filings.
Overview
The following MD&A is intended to help the reader understand the results of operations, financial condition, and cash flows of Wellstar International, Inc. MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and the accompanying notes to the financial statements ("Notes").
Background
Wellstar International Inc. ("Wellstar"), through its wholly owned subsidiary, Trillennium Medical Imaging, Inc. ("Trillennium," "TMI" or "the Company"), has developed an innovative thermal imaging system designed for the evaluation and early detection of heat patterns within the body that indicate the presence of physiological changes such as pressure ulcers, referred pain and metabolic changes within the breast. The Company's infrared imaging involves the detection and recording of skin temperature and injury patterns, providing visual and quantitative documentation to accurately capture body temperature data. The Company's system map changes in skin blood flow by translating temperature data into pictures. The interpretation of these temperatures and thermal patterns can play an important role in the development of a diagnosis. The Company's system consists of proprietary imagers ("TMI 7800 Imager"), operating software ("Image MHS 5.0 Software") and a comprehensive data transmission and collection network, for which TMI has patents pending. The Company seeks to be the first-to-market in deep tissue injury and pressure ulcer detection using its proprietary infrared imaging system. Thermal Imaging is a low cost, noncontact, non-radioactive diagnostic screening procedure designed for clinical evaluation. In addition, thermal imaging provides an ability to track the progress of therapies being utilized in a low cost, non-invasive manner. Thermal Imaging can detect signs of pressure ulcers before they are visible with the naked eye through detection of temperature changes at the site which allows for treatment of the pressure ulcer before it erupts. The TMI system can be used to scan all new patients into hospitals and long-term care facilities prior admittance and begin treating existing wounds before they are visible. The TMI technology and software is approved by the FDA as an Adjunctive Diagnostic screening procedure for early breast cancer detection, differential diagnosis of pain dysfunctions, (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and Neurological disorders), the early detection of pressure ulcers, deep tissue injuries, and bed sores, as well as orthopedic applications. The Company's imaging research concurrently looks to initiate consideration of thermography as a viable tool and a medical standard for predicting and preventing pressure ulcers in the medical community.
TMI is currently seeking financing to complete the necessary changes to the TMI System and to bring the TMI System to market. The company will initially focus is efforts on Hospitals and long term care facilities.
TMI currently has had their study completed at Duke University and the results have been submitted for publication. TMI has also started a Beta Test at a nursing home. The purpose of the Beta Test is to show the ease of use of the TMI system within the work environment. TMI has expanded their Beta Test to have an installation in a Long Term Acute Care Center.
--------------------------------------------------
Plan of Operation and Financing Needs
We presently do not have any available credit, bank financing or other external sources of liquidity. Due to our brief history and historical operating losses, our operations have not been a source of liquidity. We will need to obtain additional capital in order to expand operations and become profitable. In order to obtain capital, we may need to sell additional shares of our common stock or borrow funds from private lenders. There can be no assurance that we will be successful in obtaining additional funding.
We will still need additional capital in order to continue operations until we are able to achieve positive operating cash flow. Additional capital is being sought, but we cannot guarantee that we will be able to obtain such investments. This money would be used for the roll out of our TMI System to the long term care market.
Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. However, the trading price of our common stock and a downturn in the North American stock and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.
Results of Operations
Quarter Ended April 30, 2010 compared to Quarter Ended April 30, 2009 (all references are to the Quarter Ended April 30)
Revenue: We did not have revenue during the quarters ended April 30, 2010 and April 30, 2009.
Cost of Sales and Gross Profit: There was no Cost of Sales for the quarters ended April 30, 2010 and April 30, 2009 as we did not generate revenue during these periods.
Operating, Selling, General and Administrative Expenses: Operating, selling, general and administrative expenses decreased by $97,640, or 18% in the 2010 third fiscal quarter to $446,130 from $543,770 in 2009. This decrease reflects a decrease in stockholder relations expenses by $45,975. In addition, salaries decreased by $98,200 from $225,000 to $126,800.
Loss from Operations: Loss from operations for the quarter ended April 30, 2010 was $446,130, a decrease of $97,640 or 18% from the loss from operations in the same period in 2009 of $543,770 as a result of the aforementioned decreases in operating, sales and administrative expenses.
Other Income and Expense: Total other expenses of $17,022,080 in the quarter ended April 30, 2010 represent an increase in other expenses of $17,121,319 from the income of $99,239 in 2009 as a result of a greater expense from derivative instrument expense for the period related to a increase in derivative instrument liabilities caused by a change in our stock prices.
--------------------------------------------------
Net Loss: Net loss of $17,468,210 for the quarter ended April 30, 2010 was $17,023,679 greater than the net loss of $444,531 for the same period in 2009 due to the greater amount of derivative instrument expense.
Liquidity and Capital Resources
It is Management's opinion that the current financial position of the company is in dire straits and the Company will need to obtain additional funding to continue operations. The Company expects that it will be able to continue operating through July 2010. If the Company does not obtain financing at this time, it will be required to cease operations.
As of April 30, 2010, we had a working capital deficit of approximately $29,521,416, and cash of $176,044. We do not have the funds necessary to maintain our operations for the coming fiscal year, and will need to raise additional funding.
The liquidity impact of our outstanding debt is as follows:
Our secured convertible note with Andrew W. Thompson (the "Thompson Note"), in the principal amount of $400,000, matured on April 11, 2006 and remains outstanding. We are in default pursuant to the terms of the Thompson Note, although we have not received a notice of default from Mr. Thompson, nor has Mr. Thompson indicated to the Company that he intends to place the Company in default under the loan agreement. Interest on the Thompson Note is at the rate of 8% plus the prevailing margin rate charged to the lender, which is currently 7.625%. In addition to the outstanding principal, we also owe accrued interest in the amount of $267,290. The lender has the option of converting the loan into fully registered common stock at a discount of 40% on the day of conversion, which is the prepayment date or the due date, whichever occurs first. Additionally, the lender also received warrants to purchase 1,000,000 shares of the company's fully registered common stock at an exercise price of $0.50 per share. If the lender converts, the Company will issue the appropriate number of shares and will not be required to use cash to liquidate the debt. Additionally, the Company will receive the cash proceeds in the amount of $500,000 if the lender exercises the $0.50 warrants. On November 10, 2006, the Thompson Note was amended to include a provision stipulating that the holder may not convert the secured convertible note if such conversion or exercise would cause him to own more than 9.99% of our outstanding common stock. However, this restriction does not prevent the holder from converting a portion of the note and then converting the rest of the note. In this way, the holder could sell more than this limit while never holding more than this limit.
Our unsecured demand note with Michael Sweeney (the "Sweeney Note"), in the principal amount of $150,000, matured on August 1, 2006 and remains outstanding. In addition to the outstanding principal, we also owe accrued interest in the amount of $43,325. We are in default pursuant to the terms of the Sweeney Note and we have not received a notice of default from Mr. Sweeney, nor has Mr. Sweeney indicated to the Company that he intends to place the Company in default under the note.
Our unsecured demand note with Micro Health Systems (the "MHS Note"), dated December 21, 2005 in the principal amount of $200,000, with interest at 8% per annum, has two maturity dates: at the 180th day and the 365th day following issuance. A payment of $100,000.00 is due at each maturity date. We did not make the first or second payment. There is an acceleration provision in the MHS Note stipulating that the entire $200,000.00 was due upon non-payment of the first $100,000. The interest rate then goes to the highest rate allowed by Florida law. We received a notice of default from MHS on November 28, 2006 but no further action has been taken. The MHS Note is secured by a pledge of 1.5 million shares of the Company's treasury stock.
--------------------------------------------------
To obtain funding for our ongoing operations, we entered into a Securities Purchase Agreement with four accredited investors - AJW Partners, LLC, AJW Qualified Partners, LLC, AJW Offshore, Ltd. and New Millennium Partners II, LLC on October 31, 2005 for the sale of (i) $3,000,000 in secured convertible notes and (ii) warrants to buy 5,000,000 shares of our common stock. The gross financing proceeds were paid to the Company in three separate tranches of $1,000,000 each. The first tranche of the financing, in the amount of $1,000,000, was received by the Company upon closing. The second tranche was received on January 20, 2006. The third tranche of $50,000 was received in August 2006. The secured convertible notes issued pursuant to our October 2005 through June 2008 Securities Purchase Agreements bear interest originally at 8% but increasing to 13% effective September 8, 2009, mature three years from the date of issuance, and are convertible into our common stock, at the selling stockholders' option, at the lower of (i) $0.12 or (ii) generally a 75% discount to the average of the three lowest intraday trading prices for the common stock on a principal market for the 20 trading days before but not including the conversion date. As of May 20, 2010, the average of the three lowest intraday trading prices for our common stock during the preceding 20 trading days as reported on the Over-The-Counter Bulletin Board was $ .0006 and, therefore, the conversion price for the secured convertible notes was $ .00015. Based on this conversion price, the $4,841,799 outstanding principal amount of the secured convertible notes, excluding interest, were convertible into approximately 32,278,660,000 shares of our common stock. The stock purchase warrants have an exercise price of $0.0001 and $0.50 per share. If the lender converts, the Company will issue the appropriate number of shares and will not be required to use cash to liquidate the debt. Additionally, the Company will receive cash proceeds in the amount of $3,055,000 if the lender exercises the warrants. If the lender converts, the Company will issue the appropriate number of shares and will not be required to use the cash to liquidate the debt.
To obtain additional funding for our ongoing operations, we entered into a loan agreement with JMJ Financial a loan in the principal sum of $ 575,000, of which $ 75,000 is a loan acquisition cost. The note provides for a one time 12% interest charge on the principal sum. The convertible note is convertible into our common stock, at the selling stockholders' option, at 70% of the average of the three lowest intraday trading prices for the common stock on a principal market for the 20 trading days before but not including the conversion date. As of July 31, 2009 the principal balance of the loan is $ 750,000.
On May 15, 2009, the
Company entered into a Securities Purchase Agreement with AJW Partners, LLC ("Partners"), AJW Partners II, LLC ("Partners II "), AJW Master Fund, Ltd. ("Master"), AJW Master Fund II, Ltd. ("Master II") and New Millennium Capital Partners, II, LLC ("Millennium" and collectively with Partners, Partners II, Master and Maser II, the "Purchasers") for the sale of 13% secured convertible notes in an aggregate principal amount of up to $79,500 (the "Notes"). The Purchasers closed on $22,000 in Notes on May 18, 2009.
The Notes bear interest at the rate of 13% per annum. Interest is payable monthly, unless the Company's common stock is greater than $0.045 per share for each trading day of a month, in which event no interest is payable during such month. Any interest not paid when due shall bear interest of 15% per annum from the date due until the same is paid. The Notes mature three years from the date of issuance, and are convertible into common stock, at the Purchasers' option, at the lesser of (i) $0.12 or (ii) a 75% discount to the average of the three lowest trading prices of the common stock during the 20 trading day period prior to conversion. The Notes contain a call option whereby, if the Company's stock price is below $0.045, the Company may prepay the outstanding principal amount of the Notes, subject to the conditions set forth in the call option. The Notes also contain a partial call option whereby, if the Company's stock price is below $0.045, the Company may prepay a portion of the outstanding principal amount of the Note, subject to the conditions set forth in the partial call option.
--------------------------------------------------
The full principal amount of Notes are due upon a default under the terms of the secured convertible notes. In addition, the Company granted the Purchasers a security interest in substantially all of the Company's assets and intellectual property. The Company is required to file a registration statement with the Securities and Exchange Commission upon demand, which will include the common stock underlying the Notes.
The conversion price of the Notes may be adjusted in certain circumstances such as if the Company pays a stock dividend, subdivides or combines outstanding shares of common stock into a greater or lesser number of shares, or takes such other action as would otherwise result in dilution of the selling stockholder's position.
The Purchasers have agreed to restrict their ability to convert their Notes and receive shares of common stock such that the number of shares of common stock held by them in the aggregate and their affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common stock.
JMJ Financing
On May 22, 2009, the Company issued a Convertible Promissory Note to JMJ Financial ("JMJ") in aggregate principal amounts of $575,000 (the "Initial JMJ Note"). In consideration for Wellstar's issuing of the Initial JMJ Note, JMJ issued Wellstar a Secured and Collateralized Promissory Note in the principle amount of $500,000 (the "Initial Wellstar Note").
In addition, on August 19, 2009 Wellstar issued a Convertible Promissory Note to JMJ in aggregate principal amounts of $1,150,000 (the "Second JMJ Note" and together with the Initial JMJ Note, the "JMJ Notes"). In consideration for Wellstar's issuing of the Second JMJ Note, JMJ issued Wellstar a Secured and Collateralized Promissory Note in the principle amouns of $1,000,000 (the "Second Wellstar Note" and together with the Initial Wellstar Note, the "Wellstar Notes").
The JMJ Notes bear interest at 12%, mature three years from the date of issuance, and are convertible into our common stock, at JMJ's option, at a conversion price, equal to 70% of the lowest trade for our common stock during the 20 trading days prior to the conversion. Prior to the conversion of the JMJ Notes, JMJ must make a payment to Wellstar reducing the amount owed to Wellstar under the Wellstar Notes. As of May 20, 2010, the lowest trade for our common stock during the 20 trading days as reported on the Over-The-Counter Bulletin Board was $.0006 and, therefore, the conversion price for the JMJ Notes was $.00047. Based on this conversion price, the JMJ Notes in the aggregate amount of $1,3321,789, excluding interest, are convertible into 2,833,593,617 shares of our common stock.
--------------------------------------------------
JMJ has agreed to restrict their ability to convert the JMJ Notes and receive shares of common stock such that the number of shares of common stock held by them in the aggregate and their affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common stock.
The Wellstar Notes bear interest at the rate of 13.8% per annum and mature three years from the date of issuance. No interest or principal payments are required until the maturity date, but both principal and interest may be prepaid prior to Maturity Date. The Wellstar Notes are secured by units of STIC AIM Liquidity Portfolio Select Investment Select Investment Fund (the "JMJ Collateral"). On each of the Wellstar Notes, JMJ has agreed to pay down the principal of the Wellstar Notes commencing 210 days after the original issuance of the Wellstar Notes, however, JMJ may adjust the payment schedule within its sole discretion. In the event that JMJ defaults on the Wellstar Notes, Wellstar may take possession of the JMJ Collateral.
We presently do not have any additional available credit, bank financing or other external sources of liquidity. Due to our brief operating history as a start up company, our operations have not been a source of liquidity. We will need to obtain additional capital in order to maintain and expand our operations. We are currently investigating other financial alternatives, including additional equity and/or debt financing. In order to obtain capital, we may need to sell additional shares of our common stock or borrow funds from private lenders. However, there can be no assurance that that any additional financing will become available to us, and if available, on terms acceptable to us.
http://biz.yahoo.com/e/100621/wlsi.ob10-q.html
21-Jun-2010
Quarterly Report
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Special Note on Forward-Looking Statements
Certain statements in Management's Discussion and Analysis ("MD&A"), other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements". These forward-looking statements generally are identified by the words "believe," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. These statements are subject to a number of risks, uncertainties and developments beyond our control or foresight including changes in the trends of the mobile computing industry, formation of competitors, changes in governmental regulation or taxation, changes in our personnel and other such factors. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers should carefully review the risk factors and related notes included in the Company's Form 10-K and other SEC filings.
Overview
The following MD&A is intended to help the reader understand the results of operations, financial condition, and cash flows of Wellstar International, Inc. MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and the accompanying notes to the financial statements ("Notes").
Background
Wellstar International Inc. ("Wellstar"), through its wholly owned subsidiary, Trillennium Medical Imaging, Inc. ("Trillennium," "TMI" or "the Company"), has developed an innovative thermal imaging system designed for the evaluation and early detection of heat patterns within the body that indicate the presence of physiological changes such as pressure ulcers, referred pain and metabolic changes within the breast. The Company's infrared imaging involves the detection and recording of skin temperature and injury patterns, providing visual and quantitative documentation to accurately capture body temperature data. The Company's system map changes in skin blood flow by translating temperature data into pictures. The interpretation of these temperatures and thermal patterns can play an important role in the development of a diagnosis. The Company's system consists of proprietary imagers ("TMI 7800 Imager"), operating software ("Image MHS 5.0 Software") and a comprehensive data transmission and collection network, for which TMI has patents pending. The Company seeks to be the first-to-market in deep tissue injury and pressure ulcer detection using its proprietary infrared imaging system. Thermal Imaging is a low cost, noncontact, non-radioactive diagnostic screening procedure designed for clinical evaluation. In addition, thermal imaging provides an ability to track the progress of therapies being utilized in a low cost, non-invasive manner. Thermal Imaging can detect signs of pressure ulcers before they are visible with the naked eye through detection of temperature changes at the site which allows for treatment of the pressure ulcer before it erupts. The TMI system can be used to scan all new patients into hospitals and long-term care facilities prior admittance and begin treating existing wounds before they are visible. The TMI technology and software is approved by the FDA as an Adjunctive Diagnostic screening procedure for early breast cancer detection, differential diagnosis of pain dysfunctions, (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and Neurological disorders), the early detection of pressure ulcers, deep tissue injuries, and bed sores, as well as orthopedic applications. The Company's imaging research concurrently looks to initiate consideration of thermography as a viable tool and a medical standard for predicting and preventing pressure ulcers in the medical community.
TMI is currently seeking financing to complete the necessary changes to the TMI System and to bring the TMI System to market. The company will initially focus is efforts on Hospitals and long term care facilities.
TMI currently has had their study completed at Duke University and the results have been submitted for publication. TMI has also started a Beta Test at a nursing home. The purpose of the Beta Test is to show the ease of use of the TMI system within the work environment. TMI has expanded their Beta Test to have an installation in a Long Term Acute Care Center.
--------------------------------------------------
Plan of Operation and Financing Needs
We presently do not have any available credit, bank financing or other external sources of liquidity. Due to our brief history and historical operating losses, our operations have not been a source of liquidity. We will need to obtain additional capital in order to expand operations and become profitable. In order to obtain capital, we may need to sell additional shares of our common stock or borrow funds from private lenders. There can be no assurance that we will be successful in obtaining additional funding.
We will still need additional capital in order to continue operations until we are able to achieve positive operating cash flow. Additional capital is being sought, but we cannot guarantee that we will be able to obtain such investments. This money would be used for the roll out of our TMI System to the long term care market.
Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. However, the trading price of our common stock and a downturn in the North American stock and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.
Results of Operations
Quarter Ended April 30, 2010 compared to Quarter Ended April 30, 2009 (all references are to the Quarter Ended April 30)
Revenue: We did not have revenue during the quarters ended April 30, 2010 and April 30, 2009.
Cost of Sales and Gross Profit: There was no Cost of Sales for the quarters ended April 30, 2010 and April 30, 2009 as we did not generate revenue during these periods.
Operating, Selling, General and Administrative Expenses: Operating, selling, general and administrative expenses decreased by $97,640, or 18% in the 2010 third fiscal quarter to $446,130 from $543,770 in 2009. This decrease reflects a decrease in stockholder relations expenses by $45,975. In addition, salaries decreased by $98,200 from $225,000 to $126,800.
Loss from Operations: Loss from operations for the quarter ended April 30, 2010 was $446,130, a decrease of $97,640 or 18% from the loss from operations in the same period in 2009 of $543,770 as a result of the aforementioned decreases in operating, sales and administrative expenses.
Other Income and Expense: Total other expenses of $17,022,080 in the quarter ended April 30, 2010 represent an increase in other expenses of $17,121,319 from the income of $99,239 in 2009 as a result of a greater expense from derivative instrument expense for the period related to a increase in derivative instrument liabilities caused by a change in our stock prices.
--------------------------------------------------
Net Loss: Net loss of $17,468,210 for the quarter ended April 30, 2010 was $17,023,679 greater than the net loss of $444,531 for the same period in 2009 due to the greater amount of derivative instrument expense.
Liquidity and Capital Resources
It is Management's opinion that the current financial position of the company is in dire straits and the Company will need to obtain additional funding to continue operations. The Company expects that it will be able to continue operating through July 2010. If the Company does not obtain financing at this time, it will be required to cease operations.
As of April 30, 2010, we had a working capital deficit of approximately $29,521,416, and cash of $176,044. We do not have the funds necessary to maintain our operations for the coming fiscal year, and will need to raise additional funding.
The liquidity impact of our outstanding debt is as follows:
Our secured convertible note with Andrew W. Thompson (the "Thompson Note"), in the principal amount of $400,000, matured on April 11, 2006 and remains outstanding. We are in default pursuant to the terms of the Thompson Note, although we have not received a notice of default from Mr. Thompson, nor has Mr. Thompson indicated to the Company that he intends to place the Company in default under the loan agreement. Interest on the Thompson Note is at the rate of 8% plus the prevailing margin rate charged to the lender, which is currently 7.625%. In addition to the outstanding principal, we also owe accrued interest in the amount of $267,290. The lender has the option of converting the loan into fully registered common stock at a discount of 40% on the day of conversion, which is the prepayment date or the due date, whichever occurs first. Additionally, the lender also received warrants to purchase 1,000,000 shares of the company's fully registered common stock at an exercise price of $0.50 per share. If the lender converts, the Company will issue the appropriate number of shares and will not be required to use cash to liquidate the debt. Additionally, the Company will receive the cash proceeds in the amount of $500,000 if the lender exercises the $0.50 warrants. On November 10, 2006, the Thompson Note was amended to include a provision stipulating that the holder may not convert the secured convertible note if such conversion or exercise would cause him to own more than 9.99% of our outstanding common stock. However, this restriction does not prevent the holder from converting a portion of the note and then converting the rest of the note. In this way, the holder could sell more than this limit while never holding more than this limit.
Our unsecured demand note with Michael Sweeney (the "Sweeney Note"), in the principal amount of $150,000, matured on August 1, 2006 and remains outstanding. In addition to the outstanding principal, we also owe accrued interest in the amount of $43,325. We are in default pursuant to the terms of the Sweeney Note and we have not received a notice of default from Mr. Sweeney, nor has Mr. Sweeney indicated to the Company that he intends to place the Company in default under the note.
Our unsecured demand note with Micro Health Systems (the "MHS Note"), dated December 21, 2005 in the principal amount of $200,000, with interest at 8% per annum, has two maturity dates: at the 180th day and the 365th day following issuance. A payment of $100,000.00 is due at each maturity date. We did not make the first or second payment. There is an acceleration provision in the MHS Note stipulating that the entire $200,000.00 was due upon non-payment of the first $100,000. The interest rate then goes to the highest rate allowed by Florida law. We received a notice of default from MHS on November 28, 2006 but no further action has been taken. The MHS Note is secured by a pledge of 1.5 million shares of the Company's treasury stock.
--------------------------------------------------
To obtain funding for our ongoing operations, we entered into a Securities Purchase Agreement with four accredited investors - AJW Partners, LLC, AJW Qualified Partners, LLC, AJW Offshore, Ltd. and New Millennium Partners II, LLC on October 31, 2005 for the sale of (i) $3,000,000 in secured convertible notes and (ii) warrants to buy 5,000,000 shares of our common stock. The gross financing proceeds were paid to the Company in three separate tranches of $1,000,000 each. The first tranche of the financing, in the amount of $1,000,000, was received by the Company upon closing. The second tranche was received on January 20, 2006. The third tranche of $50,000 was received in August 2006. The secured convertible notes issued pursuant to our October 2005 through June 2008 Securities Purchase Agreements bear interest originally at 8% but increasing to 13% effective September 8, 2009, mature three years from the date of issuance, and are convertible into our common stock, at the selling stockholders' option, at the lower of (i) $0.12 or (ii) generally a 75% discount to the average of the three lowest intraday trading prices for the common stock on a principal market for the 20 trading days before but not including the conversion date. As of May 20, 2010, the average of the three lowest intraday trading prices for our common stock during the preceding 20 trading days as reported on the Over-The-Counter Bulletin Board was $ .0006 and, therefore, the conversion price for the secured convertible notes was $ .00015. Based on this conversion price, the $4,841,799 outstanding principal amount of the secured convertible notes, excluding interest, were convertible into approximately 32,278,660,000 shares of our common stock. The stock purchase warrants have an exercise price of $0.0001 and $0.50 per share. If the lender converts, the Company will issue the appropriate number of shares and will not be required to use cash to liquidate the debt. Additionally, the Company will receive cash proceeds in the amount of $3,055,000 if the lender exercises the warrants. If the lender converts, the Company will issue the appropriate number of shares and will not be required to use the cash to liquidate the debt.
To obtain additional funding for our ongoing operations, we entered into a loan agreement with JMJ Financial a loan in the principal sum of $ 575,000, of which $ 75,000 is a loan acquisition cost. The note provides for a one time 12% interest charge on the principal sum. The convertible note is convertible into our common stock, at the selling stockholders' option, at 70% of the average of the three lowest intraday trading prices for the common stock on a principal market for the 20 trading days before but not including the conversion date. As of July 31, 2009 the principal balance of the loan is $ 750,000.
On May 15, 2009, the
Company entered into a Securities Purchase Agreement with AJW Partners, LLC ("Partners"), AJW Partners II, LLC ("Partners II "), AJW Master Fund, Ltd. ("Master"), AJW Master Fund II, Ltd. ("Master II") and New Millennium Capital Partners, II, LLC ("Millennium" and collectively with Partners, Partners II, Master and Maser II, the "Purchasers") for the sale of 13% secured convertible notes in an aggregate principal amount of up to $79,500 (the "Notes"). The Purchasers closed on $22,000 in Notes on May 18, 2009.
The Notes bear interest at the rate of 13% per annum. Interest is payable monthly, unless the Company's common stock is greater than $0.045 per share for each trading day of a month, in which event no interest is payable during such month. Any interest not paid when due shall bear interest of 15% per annum from the date due until the same is paid. The Notes mature three years from the date of issuance, and are convertible into common stock, at the Purchasers' option, at the lesser of (i) $0.12 or (ii) a 75% discount to the average of the three lowest trading prices of the common stock during the 20 trading day period prior to conversion. The Notes contain a call option whereby, if the Company's stock price is below $0.045, the Company may prepay the outstanding principal amount of the Notes, subject to the conditions set forth in the call option. The Notes also contain a partial call option whereby, if the Company's stock price is below $0.045, the Company may prepay a portion of the outstanding principal amount of the Note, subject to the conditions set forth in the partial call option.
--------------------------------------------------
The full principal amount of Notes are due upon a default under the terms of the secured convertible notes. In addition, the Company granted the Purchasers a security interest in substantially all of the Company's assets and intellectual property. The Company is required to file a registration statement with the Securities and Exchange Commission upon demand, which will include the common stock underlying the Notes.
The conversion price of the Notes may be adjusted in certain circumstances such as if the Company pays a stock dividend, subdivides or combines outstanding shares of common stock into a greater or lesser number of shares, or takes such other action as would otherwise result in dilution of the selling stockholder's position.
The Purchasers have agreed to restrict their ability to convert their Notes and receive shares of common stock such that the number of shares of common stock held by them in the aggregate and their affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common stock.
JMJ Financing
On May 22, 2009, the Company issued a Convertible Promissory Note to JMJ Financial ("JMJ") in aggregate principal amounts of $575,000 (the "Initial JMJ Note"). In consideration for Wellstar's issuing of the Initial JMJ Note, JMJ issued Wellstar a Secured and Collateralized Promissory Note in the principle amount of $500,000 (the "Initial Wellstar Note").
In addition, on August 19, 2009 Wellstar issued a Convertible Promissory Note to JMJ in aggregate principal amounts of $1,150,000 (the "Second JMJ Note" and together with the Initial JMJ Note, the "JMJ Notes"). In consideration for Wellstar's issuing of the Second JMJ Note, JMJ issued Wellstar a Secured and Collateralized Promissory Note in the principle amouns of $1,000,000 (the "Second Wellstar Note" and together with the Initial Wellstar Note, the "Wellstar Notes").
The JMJ Notes bear interest at 12%, mature three years from the date of issuance, and are convertible into our common stock, at JMJ's option, at a conversion price, equal to 70% of the lowest trade for our common stock during the 20 trading days prior to the conversion. Prior to the conversion of the JMJ Notes, JMJ must make a payment to Wellstar reducing the amount owed to Wellstar under the Wellstar Notes. As of May 20, 2010, the lowest trade for our common stock during the 20 trading days as reported on the Over-The-Counter Bulletin Board was $.0006 and, therefore, the conversion price for the JMJ Notes was $.00047. Based on this conversion price, the JMJ Notes in the aggregate amount of $1,3321,789, excluding interest, are convertible into 2,833,593,617 shares of our common stock.
--------------------------------------------------
JMJ has agreed to restrict their ability to convert the JMJ Notes and receive shares of common stock such that the number of shares of common stock held by them in the aggregate and their affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common stock.
The Wellstar Notes bear interest at the rate of 13.8% per annum and mature three years from the date of issuance. No interest or principal payments are required until the maturity date, but both principal and interest may be prepaid prior to Maturity Date. The Wellstar Notes are secured by units of STIC AIM Liquidity Portfolio Select Investment Select Investment Fund (the "JMJ Collateral"). On each of the Wellstar Notes, JMJ has agreed to pay down the principal of the Wellstar Notes commencing 210 days after the original issuance of the Wellstar Notes, however, JMJ may adjust the payment schedule within its sole discretion. In the event that JMJ defaults on the Wellstar Notes, Wellstar may take possession of the JMJ Collateral.
We presently do not have any additional available credit, bank financing or other external sources of liquidity. Due to our brief operating history as a start up company, our operations have not been a source of liquidity. We will need to obtain additional capital in order to maintain and expand our operations. We are currently investigating other financial alternatives, including additional equity and/or debt financing. In order to obtain capital, we may need to sell additional shares of our common stock or borrow funds from private lenders. However, there can be no assurance that that any additional financing will become available to us, and if available, on terms acceptable to us.
23.06.10 12:47
#72
Menne
Wellstar International, Inc. Shareholder Update
in Kürze:
- The timing of the publication coincides with our new camera being completed and ready for mass production
- we have contracted with a multi billion dollar manufacturer
- reduce the cost of the system by more than 40%
- The company expects to be cash flow positive within 3 months of our initial launch
- Wellstar will start full scale marketing in November of 2010
Hier der ganze Text:
John Antonio, CEO of Wellstar International, Inc. (OTCBB: WLSI), today issued the following statement:
As the CEO of Wellstar, I wanted to take the time to update all of our shareholders with the current status of the company, as well as the direction of where the company is headed.
We have been working very hard to have our Trillennium Medical Imaging System ready to go to market. As most are aware we have been waiting for the Duke Study to be published in the ADVANCES IN SKIN AND WOUND CARE PUBLICATION JOURNAL. While everything has been submitted to the publisher and there have been two rounds of questions and clarifications resubmitted, we are confident and excited that we will have the results published in August or September. This will obviously be a very important milestone for Wellstar International as this independent report will validate the results we have been seeing and reinforce the demand for our Trillennium Medical Imaging System in the marketplace.
The timing of the publication coincides with our new camera being completed and ready for mass production. As previously announced, we have contracted with a multi billion dollar manufacturer to have the camera designed to be market ready and user friendly. Up until this point, we have been in Beta Tests and getting good results with our current camera. This testing period has given us the ability to learn how to improve the system in our target work environment and we have done so. We have been able to design a better camera specifically made for our market which is Hospitals, Nursing Homes and Long Term Care Facilities (LTAC). We also have been able to reduce the cost of the system by more than 40%. When the company starts to place systems with the price savings our path to profitability will be very quick. The company expects to be cash flow positive within 3 months of our initial launch.
The company will continue to market its new system to hospitals, nursing homes and long term care facilities for installations starting in November. In the interim, we will continue ongoing trials and additional beta testing in facilities with our existing system.
To recap, Wellstar is well positioned to be the first to market with a system that can predict deep tissue injury that leads to pressure ulcers or bed soars. Wellstar will start full scale marketing in November of 2010 upon the publication of the results of the Duke Study and the new TMI Camera being ready for mass production. This is a very exciting time for Wellstar and its shareholders. We have worked very hard to get to this point. It may have taken longer than anticipated, but we have remained steadfast to our goal to be first to market with a superior product and we are nearing that point. Your constant support is appreciated and we look to a very successful 2nd half of 2010.
Wellstar will be making announcements to the public as they achieve any significant progress in the process of rollout and installation of their systems.
John Antonio
Chief Executive Officer
Wellstar International, Inc.
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results.
Website is www.wellstar.us
http://www.finanzen.net/nachricht/...al-Inc-Shareholder-Update-815571
- The timing of the publication coincides with our new camera being completed and ready for mass production
- we have contracted with a multi billion dollar manufacturer
- reduce the cost of the system by more than 40%
- The company expects to be cash flow positive within 3 months of our initial launch
- Wellstar will start full scale marketing in November of 2010
Hier der ganze Text:
John Antonio, CEO of Wellstar International, Inc. (OTCBB: WLSI), today issued the following statement:
As the CEO of Wellstar, I wanted to take the time to update all of our shareholders with the current status of the company, as well as the direction of where the company is headed.
We have been working very hard to have our Trillennium Medical Imaging System ready to go to market. As most are aware we have been waiting for the Duke Study to be published in the ADVANCES IN SKIN AND WOUND CARE PUBLICATION JOURNAL. While everything has been submitted to the publisher and there have been two rounds of questions and clarifications resubmitted, we are confident and excited that we will have the results published in August or September. This will obviously be a very important milestone for Wellstar International as this independent report will validate the results we have been seeing and reinforce the demand for our Trillennium Medical Imaging System in the marketplace.
The timing of the publication coincides with our new camera being completed and ready for mass production. As previously announced, we have contracted with a multi billion dollar manufacturer to have the camera designed to be market ready and user friendly. Up until this point, we have been in Beta Tests and getting good results with our current camera. This testing period has given us the ability to learn how to improve the system in our target work environment and we have done so. We have been able to design a better camera specifically made for our market which is Hospitals, Nursing Homes and Long Term Care Facilities (LTAC). We also have been able to reduce the cost of the system by more than 40%. When the company starts to place systems with the price savings our path to profitability will be very quick. The company expects to be cash flow positive within 3 months of our initial launch.
The company will continue to market its new system to hospitals, nursing homes and long term care facilities for installations starting in November. In the interim, we will continue ongoing trials and additional beta testing in facilities with our existing system.
To recap, Wellstar is well positioned to be the first to market with a system that can predict deep tissue injury that leads to pressure ulcers or bed soars. Wellstar will start full scale marketing in November of 2010 upon the publication of the results of the Duke Study and the new TMI Camera being ready for mass production. This is a very exciting time for Wellstar and its shareholders. We have worked very hard to get to this point. It may have taken longer than anticipated, but we have remained steadfast to our goal to be first to market with a superior product and we are nearing that point. Your constant support is appreciated and we look to a very successful 2nd half of 2010.
Wellstar will be making announcements to the public as they achieve any significant progress in the process of rollout and installation of their systems.
John Antonio
Chief Executive Officer
Wellstar International, Inc.
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results.
Website is www.wellstar.us
http://www.finanzen.net/nachricht/...al-Inc-Shareholder-Update-815571
22.07.10 15:25
#73
Menne
WLSI Announces Receipt of New Camera Prototypes
Wellstar Announces Receipt of New Camera Prototypes
Date : 07/21/2010 @ 11:00AM
Source : Business Wire
Stock : Wellstar (WLSI)
Quote : 0.0002 0.0 (0.00%) @ 1:24PM
Wellstar Announces Receipt of New Camera Prototypes
Wellstar International Inc. (BB) (OTCBB:WLSI)
Intraday Stock Chart
Today : Thursday 22 July 2010
Wellstar (OTCBB:WLSI) through its wholly owned subsidiary Trillennium Medical Imaging (TMI) announces the Delivery of 2 Prototypes of the TMI Clinical Camera Design.
As earlier announced TMI has contracted for a new camera to be developed under their specific design for clinical use. The manufacturer has delivered the first prototypes for approval.
John Antonio, President and CEO of TMI stated, "The prototypes delivered are everything that we wanted and production should be completed in the month of October as planned.
"By designing our own clinical version of the camera, we will control all aspects of our Imaging System and have the flexibility to incorporate all of the necessary functions to provide an innovative, bedside solution for the early detection of pressure ulcers. We will be able to seamlessly integrate into any Health Information System (HIS) that uses a barcode for patient identification, get immediate, real time analysis of the images at the bedside, and provide a means of documentation and data storage for the facility. This will provide health care officials with a multi-faceted tool that does the following:
Determines if a specific anatomic location has patterns of injury associated with the development of a pressure ulcer.
Provides the nursing staff and physicians with an immediate bedside analysis so that best practices can be implemented to prevent further skin damage and pressure ulcers.
Provides documentation to the administration that includes data interpretation of the image, time the image was acquired, and a full report analysis that can be attached to the patients’ permanent record.
Lowers the cost per unit by more than 40% to the company, thus giving the company a quicker path to profitability.
Make the system affordable to most users.
"This will be a valuable tool in assessing patients that are admitted to a facility, daily skin assessments, and documenting patient condition upon discharge. This will provide patients with the highest level of care, while documenting every aspect of the process for the facility."
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results.
Website is www.wellstar.us
http://ih.advfn.com/...mona&article=43679823&symbol=NB%5EWLSI
Date : 07/21/2010 @ 11:00AM
Source : Business Wire
Stock : Wellstar (WLSI)
Quote : 0.0002 0.0 (0.00%) @ 1:24PM
Wellstar Announces Receipt of New Camera Prototypes
Wellstar International Inc. (BB) (OTCBB:WLSI)
Intraday Stock Chart
Today : Thursday 22 July 2010
Wellstar (OTCBB:WLSI) through its wholly owned subsidiary Trillennium Medical Imaging (TMI) announces the Delivery of 2 Prototypes of the TMI Clinical Camera Design.
As earlier announced TMI has contracted for a new camera to be developed under their specific design for clinical use. The manufacturer has delivered the first prototypes for approval.
John Antonio, President and CEO of TMI stated, "The prototypes delivered are everything that we wanted and production should be completed in the month of October as planned.
"By designing our own clinical version of the camera, we will control all aspects of our Imaging System and have the flexibility to incorporate all of the necessary functions to provide an innovative, bedside solution for the early detection of pressure ulcers. We will be able to seamlessly integrate into any Health Information System (HIS) that uses a barcode for patient identification, get immediate, real time analysis of the images at the bedside, and provide a means of documentation and data storage for the facility. This will provide health care officials with a multi-faceted tool that does the following:
Determines if a specific anatomic location has patterns of injury associated with the development of a pressure ulcer.
Provides the nursing staff and physicians with an immediate bedside analysis so that best practices can be implemented to prevent further skin damage and pressure ulcers.
Provides documentation to the administration that includes data interpretation of the image, time the image was acquired, and a full report analysis that can be attached to the patients’ permanent record.
Lowers the cost per unit by more than 40% to the company, thus giving the company a quicker path to profitability.
Make the system affordable to most users.
"This will be a valuable tool in assessing patients that are admitted to a facility, daily skin assessments, and documenting patient condition upon discharge. This will provide patients with the highest level of care, while documenting every aspect of the process for the facility."
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results.
Website is www.wellstar.us
http://ih.advfn.com/...mona&article=43679823&symbol=NB%5EWLSI
11.08.10 12:06
#74
Menne
Wellstar Establishes Data Storage for Images
Date : 08/10/2010 @ 3:50PM
Source : Business Wire
Stock : Wellstar International, Inc. (WLSI)
Quote : 0.0002 0.0001 (100.00%) @ 7:02PM
Wellstar Establishes Data Storage for Images
Wellstar International Inc. (BB) (OTCBB:WLSI)
Intraday Stock Chart
Today : Wednesday 11 August 2010
Wellstar (OTCBB:WLSI), through its wholly owned subsidiary Trillennium Medical Imaging (TMI), announces plans to transition to a virtual cloud data system in conjunction with the launch of the revised camera system. The implementation of a TMI Virtual Cloud Data System will provide the framework to meet TMI’s data needs for initial rollout and well into the future. The system meets all of TMI’s requirements for corporate data, patient data, and other Federal regulations. Cloud based systems are the future of data processing and the TMI Virtual Cloud Data System will provide the foundation for the future growth of the company.
The system will be infinitely scalable and will allow TMI to rapidly add an unlimited amount of new accounts without data storage constraints. The server will have built in redundancy with a backup server located 600 to 800 miles away. This disaster recovery plan allows for instantaneous back up of all data streams and can be managed remotely. The servers will be maintained 24/7 by the host.
John Antonio, CEO of TMI states: “With the constant changes in the healthcare environment, it is essential to have detailed documentation of patient information. TMI’s imaging system captures and stores valuable information with every image that is acquired. It is our job to ensure that this acquired data is stored properly and available to our clients at any time. Our database structure will allow healthcare professionals to access digital images, thermal images, data algorithm results, along with the time and date of the image acquisition 24 hours a day, seven days a week, from anywhere in the world. We anticipate exponential growth once production begins, and moving towards this structure will allow TMI to accommodate our clients’ needs in timely manner.”
This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results.
Website is www.wellstar.us.
http://ih.advfn.com/...mona&article=43951742&symbol=NB%5EWLSI
Source : Business Wire
Stock : Wellstar International, Inc. (WLSI)
Quote : 0.0002 0.0001 (100.00%) @ 7:02PM
Wellstar Establishes Data Storage for Images
Wellstar International Inc. (BB) (OTCBB:WLSI)
Intraday Stock Chart
Today : Wednesday 11 August 2010
Wellstar (OTCBB:WLSI), through its wholly owned subsidiary Trillennium Medical Imaging (TMI), announces plans to transition to a virtual cloud data system in conjunction with the launch of the revised camera system. The implementation of a TMI Virtual Cloud Data System will provide the framework to meet TMI’s data needs for initial rollout and well into the future. The system meets all of TMI’s requirements for corporate data, patient data, and other Federal regulations. Cloud based systems are the future of data processing and the TMI Virtual Cloud Data System will provide the foundation for the future growth of the company.
The system will be infinitely scalable and will allow TMI to rapidly add an unlimited amount of new accounts without data storage constraints. The server will have built in redundancy with a backup server located 600 to 800 miles away. This disaster recovery plan allows for instantaneous back up of all data streams and can be managed remotely. The servers will be maintained 24/7 by the host.
John Antonio, CEO of TMI states: “With the constant changes in the healthcare environment, it is essential to have detailed documentation of patient information. TMI’s imaging system captures and stores valuable information with every image that is acquired. It is our job to ensure that this acquired data is stored properly and available to our clients at any time. Our database structure will allow healthcare professionals to access digital images, thermal images, data algorithm results, along with the time and date of the image acquisition 24 hours a day, seven days a week, from anywhere in the world. We anticipate exponential growth once production begins, and moving towards this structure will allow TMI to accommodate our clients’ needs in timely manner.”
This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results.
Website is www.wellstar.us.
http://ih.advfn.com/...mona&article=43951742&symbol=NB%5EWLSI
21.08.10 14:28
#75
Menne
Current report filing (8-K)
Date : 08/19/2010 @ 11:29PM
Source : Edgar (US Regulatory)
Stock : (WLSI)
Quote : 0.0002 0.0 (0.00%) @ 9:56PM
- Current report filing (8-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported): August 17, 2010
WELLSTAR INTERNATIONAL, INC.
(Exact name of registrant as specified in charter)
Nevada 333-130295 20-1834908
(State or Other Jurisdiction of
Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
6911 Pilliod Road
Holland, Ohio 43528
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (419) 865-0069
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------
Item 1.01 Entry Into A Material Definitive Agreement
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Increase to Authorized
On August 18, 2010, Wellstar International, Inc. (the “Company”) amended its certificate of incorporation to increase its authorized shares of common stock from 5,000,000,000 to 15,000,000,000 (the “Increase Amendment”). The Increase Amendment was approved by the board of directors as well as the shareholders holding a majority of the issued and outstanding shares of common stock pursuant to a written consent dated August 18, 2010.
Series C Preferred Stock
On August 17, 2010, the Company entered into conversion agreements with John Antonio (“Antonio”) and Kenneth McCoppen (“McCoppen”), both executive officers and directors of the Company, pursuant to which the Company agreed to convert $150,000 in outstanding wages owed to McCoppen and $50,000 in outstanding wages owed to Antonio into a total of 200,000 shares of Series C Preferred Stock.
The above transactions were approved by the Board of Directors of the Company. The Series C Preferred Stock does not pay dividends but each holder of Series C Preferred Stock shall be entitled to 1000 votes for each share of common stock that the Series C Preferred Stock shall be convertible into. The Series C Preferred Stock has a conversion price of $0.001 (the “Conversion Price”) and a stated value of $1.00 (the “Stated Value”). Each share of Series C Preferred Stock is convertible, at the option of the holder, into such number of shares of common stock of the Company as determined by dividing the Stated Value by the Conversion Price. The Series C Preferred Stock has no liquidation preference.
The issuance of the Series C Preferred Stock was made in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933 and Rule 506 promulgated under Regulation D thereunder. The holders of Series C Preferred Stock are accredited investors as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933.
The foregoing information is a summary of each of the agreements involved in the transactions described above, is not complete, and is qualified in its entirety by reference to the full text of those agreements, each of which is attached an exhibit to this Current Report on Form 8-K. Readers should review those agreements for a complete understanding of the terms and conditions associated with this transaction.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
Source : Edgar (US Regulatory)
Stock : (WLSI)
Quote : 0.0002 0.0 (0.00%) @ 9:56PM
- Current report filing (8-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported): August 17, 2010
WELLSTAR INTERNATIONAL, INC.
(Exact name of registrant as specified in charter)
Nevada 333-130295 20-1834908
(State or Other Jurisdiction of
Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
6911 Pilliod Road
Holland, Ohio 43528
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (419) 865-0069
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------
Item 1.01 Entry Into A Material Definitive Agreement
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Increase to Authorized
On August 18, 2010, Wellstar International, Inc. (the “Company”) amended its certificate of incorporation to increase its authorized shares of common stock from 5,000,000,000 to 15,000,000,000 (the “Increase Amendment”). The Increase Amendment was approved by the board of directors as well as the shareholders holding a majority of the issued and outstanding shares of common stock pursuant to a written consent dated August 18, 2010.
Series C Preferred Stock
On August 17, 2010, the Company entered into conversion agreements with John Antonio (“Antonio”) and Kenneth McCoppen (“McCoppen”), both executive officers and directors of the Company, pursuant to which the Company agreed to convert $150,000 in outstanding wages owed to McCoppen and $50,000 in outstanding wages owed to Antonio into a total of 200,000 shares of Series C Preferred Stock.
The above transactions were approved by the Board of Directors of the Company. The Series C Preferred Stock does not pay dividends but each holder of Series C Preferred Stock shall be entitled to 1000 votes for each share of common stock that the Series C Preferred Stock shall be convertible into. The Series C Preferred Stock has a conversion price of $0.001 (the “Conversion Price”) and a stated value of $1.00 (the “Stated Value”). Each share of Series C Preferred Stock is convertible, at the option of the holder, into such number of shares of common stock of the Company as determined by dividing the Stated Value by the Conversion Price. The Series C Preferred Stock has no liquidation preference.
The issuance of the Series C Preferred Stock was made in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933 and Rule 506 promulgated under Regulation D thereunder. The holders of Series C Preferred Stock are accredited investors as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933.
The foregoing information is a summary of each of the agreements involved in the transactions described above, is not complete, and is qualified in its entirety by reference to the full text of those agreements, each of which is attached an exhibit to this Current Report on Form 8-K. Readers should review those agreements for a complete understanding of the terms and conditions associated with this transaction.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
02.09.10 11:51
#76
Menne
CEO Message 08/01/2010
Hört sich vielversprechend an. Vllt brings der September
As the CEO of Wellstar, I wanted to take the time to provide a current update of events at the company.
We have been working very hard to have our Trillennium Medical Imaging (TMI) System ready to go to market. We are anxiously awaiting the Duke Study on our TMI System to be published in the ADVANCES IN SKIN AND WOUND CARE PUBLICATION JOURNAL. We have answered several rounds of questions and are confident that we will have the results published in August or September. This will obviously be a very important milestone for Wellstar International as this independent report will validate the results we have been seeing and reinforce the demand for our Trillennium Medical Imaging System in the marketplace.
The timing of the publication coincides with our new camera being completed and ready for mass production. As previously announced, we have contracted with a multibillion dollar manufacturer to have the camera designed to be market ready and user friendly. Up until this point, we have been in Beta Tests and getting good results with our current camera. This testing period has given us the ability to learn how to improve the system in our target work environment and we have done so. We have been able to design a better camera specifically made for our market which includes Hospitals, Nursing Homes and Long Term Care Facilities (LTAC). We also have been able to reduce the cost of the system by more than 40%. When the company starts to place systems with the price savings our path to profitability will be very quick. The company expects to be cash flow positive within 3 months of our initial launch.
The company will continue to market its new system to hospitals, nursing homes and long term care facilities for installations starting in November. In the interim, we will continue ongoing trials and additional beta testing in facilities with our existing system.
To recap, Wellstar is well positioned to be the first to market with a system that can predict deep tissue injury that leads to pressure ulcers or bed sores. Wellstar will start full scale marketing in November of 2010 upon the publication of the results of the Duke Study and the new TMI Camera being ready for mass production. This is a very exciting time for Wellstar and its shareholders. We have worked very hard to get to this point and have remained steadfast to our goal to be first to market with a superior product and we are nearing that point. Your constant support is greatly appreciated and we look to a very successful 2nd half of 2010.
Regards:
John Antonio
Chief Executive Officer
Wellstar International, Inc.
As the CEO of Wellstar, I wanted to take the time to provide a current update of events at the company.
We have been working very hard to have our Trillennium Medical Imaging (TMI) System ready to go to market. We are anxiously awaiting the Duke Study on our TMI System to be published in the ADVANCES IN SKIN AND WOUND CARE PUBLICATION JOURNAL. We have answered several rounds of questions and are confident that we will have the results published in August or September. This will obviously be a very important milestone for Wellstar International as this independent report will validate the results we have been seeing and reinforce the demand for our Trillennium Medical Imaging System in the marketplace.
The timing of the publication coincides with our new camera being completed and ready for mass production. As previously announced, we have contracted with a multibillion dollar manufacturer to have the camera designed to be market ready and user friendly. Up until this point, we have been in Beta Tests and getting good results with our current camera. This testing period has given us the ability to learn how to improve the system in our target work environment and we have done so. We have been able to design a better camera specifically made for our market which includes Hospitals, Nursing Homes and Long Term Care Facilities (LTAC). We also have been able to reduce the cost of the system by more than 40%. When the company starts to place systems with the price savings our path to profitability will be very quick. The company expects to be cash flow positive within 3 months of our initial launch.
The company will continue to market its new system to hospitals, nursing homes and long term care facilities for installations starting in November. In the interim, we will continue ongoing trials and additional beta testing in facilities with our existing system.
To recap, Wellstar is well positioned to be the first to market with a system that can predict deep tissue injury that leads to pressure ulcers or bed sores. Wellstar will start full scale marketing in November of 2010 upon the publication of the results of the Duke Study and the new TMI Camera being ready for mass production. This is a very exciting time for Wellstar and its shareholders. We have worked very hard to get to this point and have remained steadfast to our goal to be first to market with a superior product and we are nearing that point. Your constant support is greatly appreciated and we look to a very successful 2nd half of 2010.
Regards:
John Antonio
Chief Executive Officer
Wellstar International, Inc.
27.09.10 22:23
#77
Menne
Wellstar Announces New Website
Ist sie nicht schön ????
Die sollten lieber mal gute Neuigkeiten auf ihre neue Webseite schreiben.
Wellstar Announces New Website
Wellstar International Inc. (BB) (OTCBB:WLSI)
Today : Monday 27 September 2010
Wellstar (OTCBB: WLSI) through its wholly owned subsidiary Trillennium Medical Imaging (TMI) announces that they have implemented a new website.
The new website can be viewed at www.wellstar.us.
John Antonio, CEO of TMI states: “With our new Imaging system getting closer to roll out, the company will be making a full scale marketing effort to the medical community. While educating the marketplace on how our system can be utilized to increase revenues and prevent pressure ulcers from breaking the skin, the company needed to update it’s website to be more informational and user friendly. Included in the website are two videos. One video is a demonstration of the system and the other video is an interview with me. This is the company’s first step to go to market.”
......
http://ih.advfn.com/...mona&article=44535133&symbol=NB%5EWLSI
Die sollten lieber mal gute Neuigkeiten auf ihre neue Webseite schreiben.
Wellstar Announces New Website
Wellstar International Inc. (BB) (OTCBB:WLSI)
Today : Monday 27 September 2010
Wellstar (OTCBB: WLSI) through its wholly owned subsidiary Trillennium Medical Imaging (TMI) announces that they have implemented a new website.
The new website can be viewed at www.wellstar.us.
John Antonio, CEO of TMI states: “With our new Imaging system getting closer to roll out, the company will be making a full scale marketing effort to the medical community. While educating the marketplace on how our system can be utilized to increase revenues and prevent pressure ulcers from breaking the skin, the company needed to update it’s website to be more informational and user friendly. Included in the website are two videos. One video is a demonstration of the system and the other video is an interview with me. This is the company’s first step to go to market.”
......
http://ih.advfn.com/...mona&article=44535133&symbol=NB%5EWLSI
29.09.10 16:23
#78
Menne
Duke Report Accepted
Wellstar International, Inc. Announces the Results for Publication of the Duke University Study Have Been Accepted
Wellstar International Inc. (OTCBB:WLSI) announces that the publication of “Advances of Skin and Wound Care” medical journal has approved the manuscript submitted and will be publishing the results of the Duke Study.
The company has just been informed that, after several months of review and two rounds of questions and answers, the leading publication in wound care has informed the authors of the manuscript written based on the results of the completed Duke Study, that after careful review they feel it will make a valuable contribution to Advances in Skin and Wound Care Journal to publish the findings of the Duke Study.
John Antonio, CEO of Wellstar and TMI states, “This is a monumental time for us. We have been working very hard to deliver a finished product that would be acceptable to the medical market, with emphasis on the hospital and long term care industry. While we have had excellent White Papers to share during our presentations, we now have the leading medical journal on wounds publishing our results. This will open up the market to us and we can start to pursue discussing firm placements with the prospective clients which include every hospital in the United States. Our next major step is the completion of our new camera which should be completed and tested by the end of November 2010. This will allow us to start our roll out of our systems in the first quarter of 2011.”
When the company receives the firm date of the publication, it will be announced.
http://ih.advfn.com/...mona&article=44572285&symbol=NB%5EWLSI
Wellstar International Inc. (OTCBB:WLSI) announces that the publication of “Advances of Skin and Wound Care” medical journal has approved the manuscript submitted and will be publishing the results of the Duke Study.
The company has just been informed that, after several months of review and two rounds of questions and answers, the leading publication in wound care has informed the authors of the manuscript written based on the results of the completed Duke Study, that after careful review they feel it will make a valuable contribution to Advances in Skin and Wound Care Journal to publish the findings of the Duke Study.
John Antonio, CEO of Wellstar and TMI states, “This is a monumental time for us. We have been working very hard to deliver a finished product that would be acceptable to the medical market, with emphasis on the hospital and long term care industry. While we have had excellent White Papers to share during our presentations, we now have the leading medical journal on wounds publishing our results. This will open up the market to us and we can start to pursue discussing firm placements with the prospective clients which include every hospital in the United States. Our next major step is the completion of our new camera which should be completed and tested by the end of November 2010. This will allow us to start our roll out of our systems in the first quarter of 2011.”
When the company receives the firm date of the publication, it will be announced.
http://ih.advfn.com/...mona&article=44572285&symbol=NB%5EWLSI
12.10.10 19:16
#79
Schnöfnase
IHUB
Aceacebaby Member Profile Aceacebaby Share Sunday, October 10, 2010 12:09:15 PM
Re: slojab post# 6516 Post # of 6529
MESSAGE FROM ADVANCES IN SKIN AND WOUND CARE
Hello Amy,
Thank you for your inquiry. As I'm sure you know, we plan our issues far in advance. We've already begun working on 2011 issues. Because the article was just accepted, I do not have a targeted date as yet but I am going to try to get it published within the first half of 2011. Once we begin the editing process, we'll be in contact with the lead author. I understand there is interest re: the study so I'll keep that in mind as I consider my upcoming content.
Best regards,
Kathleen A. Greaves
Senior Managing Editor
Advances in Skin & Wound Care
Wolters Kluwer Health Medical Research
Lippincott, Williams & Wilkins
323 Norristown Road, Suite 200
Ambler, PA 19002
215-628-7772 tel
215-367-2147 fax
Kathleen.Greaves@wolterskluwer.com
Re: slojab post# 6516 Post # of 6529
MESSAGE FROM ADVANCES IN SKIN AND WOUND CARE
Hello Amy,
Thank you for your inquiry. As I'm sure you know, we plan our issues far in advance. We've already begun working on 2011 issues. Because the article was just accepted, I do not have a targeted date as yet but I am going to try to get it published within the first half of 2011. Once we begin the editing process, we'll be in contact with the lead author. I understand there is interest re: the study so I'll keep that in mind as I consider my upcoming content.
Best regards,
Kathleen A. Greaves
Senior Managing Editor
Advances in Skin & Wound Care
Wolters Kluwer Health Medical Research
Lippincott, Williams & Wilkins
323 Norristown Road, Suite 200
Ambler, PA 19002
215-628-7772 tel
215-367-2147 fax
Kathleen.Greaves@wolterskluwer.com
12.10.10 19:25
#80
Schnöfnase
Übersetzung zum vorherigen text
Ist zwar nur sinngemäß aber besser wie nix
hallo Amy
Danke für ihre Anfrage.Wie Sie sicher wissen planen wir unsere Beiträge weit im voraus.Wir sind momentan in den Planungen für unsere Beiträge in 2o11.Da der Artikel gerade erst akzeptiert wurde , habe ich noch kein festen Zeitpunkt für die Veröffentlichung,aber ich versuche ihn im ersten Quartal 2o11 zu veröffentlichen.Sobald wir mit dem Überarbeiten des Artikels beginnen (also in ein lesbares format bringen )werden wir Kontakt mit dem Autor aufnehmen .Ich verstehe das Interesse an der Veröffentlichung des Artikels/Studie.Aus diesem Grund werde ich dies im Hinterkopf behalten wenn es um die Nächsten Themen geht.
ist wie gesagt nicht haargenau übersetzt also ...
greets Schnöf
hallo Amy
Danke für ihre Anfrage.Wie Sie sicher wissen planen wir unsere Beiträge weit im voraus.Wir sind momentan in den Planungen für unsere Beiträge in 2o11.Da der Artikel gerade erst akzeptiert wurde , habe ich noch kein festen Zeitpunkt für die Veröffentlichung,aber ich versuche ihn im ersten Quartal 2o11 zu veröffentlichen.Sobald wir mit dem Überarbeiten des Artikels beginnen (also in ein lesbares format bringen )werden wir Kontakt mit dem Autor aufnehmen .Ich verstehe das Interesse an der Veröffentlichung des Artikels/Studie.Aus diesem Grund werde ich dies im Hinterkopf behalten wenn es um die Nächsten Themen geht.
ist wie gesagt nicht haargenau übersetzt also ...
greets Schnöf
18.10.10 20:18
#81
Schnöfnase
Aus Yahoo finance
von dem User Mhas1 der wohl ebenfalls per email in Kontakt mit der Advances in Skin and Wound care steht.
http://messages.finance.yahoo.com/...f=3&rt=2&frt=2&off=1
The journal editors told me that the Duke study is currently scheduled for publication in the summer of 2011. I don't know which month, but hopefully May or June. Duke Univ. may be able to negociate with the journal to have it published sooner (of course this must be requested and funded by wellstar). I have no idea if such a request has been placed.
As for the market penetration, you should understand that medical thermal immaging is not a new technology, it has been in use since 1982 soon after the technology was approved by FDA. However, wellstar has found a new application for the technology, that is the diagnosis of pressure ulcers. The technology has been used for many other application such as the early breast cancer detection, differential diagnosis of pain dysfunctions, (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and Neurological disorders),as well as orthopedic applications and lately the wellstar developed application for the early detection of pressure ulcers and deep tissue injuries.
Other than early detection of pressure ulcers and deep tissue injuries, the market is saturated with devices from multi-billion-dollar companies.
The pressure ulcer application is unique to wellstar and it is a huge market if you consider the worldwide need for it. Over the years wellstar can be a muli-billion-dollar company.
With regard to the existing applications, wellstar must provide services at a deep discout from their competitors.
The most difficult time for wellstar is the next 6 months, if they could get their product to roll out, the rest is easy, so I would say give it 6-12 months, it is one of the few penny stocks that have a good potential. The Duke study is the assurance for their technology.
Our biggest risk at this time is if Antonio makes an idiotic decision to excercise a R/S, this will dash the hopes of all shareholders.
glta
http://messages.finance.yahoo.com/...f=3&rt=2&frt=2&off=1
The journal editors told me that the Duke study is currently scheduled for publication in the summer of 2011. I don't know which month, but hopefully May or June. Duke Univ. may be able to negociate with the journal to have it published sooner (of course this must be requested and funded by wellstar). I have no idea if such a request has been placed.
As for the market penetration, you should understand that medical thermal immaging is not a new technology, it has been in use since 1982 soon after the technology was approved by FDA. However, wellstar has found a new application for the technology, that is the diagnosis of pressure ulcers. The technology has been used for many other application such as the early breast cancer detection, differential diagnosis of pain dysfunctions, (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and Neurological disorders),as well as orthopedic applications and lately the wellstar developed application for the early detection of pressure ulcers and deep tissue injuries.
Other than early detection of pressure ulcers and deep tissue injuries, the market is saturated with devices from multi-billion-dollar companies.
The pressure ulcer application is unique to wellstar and it is a huge market if you consider the worldwide need for it. Over the years wellstar can be a muli-billion-dollar company.
With regard to the existing applications, wellstar must provide services at a deep discout from their competitors.
The most difficult time for wellstar is the next 6 months, if they could get their product to roll out, the rest is easy, so I would say give it 6-12 months, it is one of the few penny stocks that have a good potential. The Duke study is the assurance for their technology.
Our biggest risk at this time is if Antonio makes an idiotic decision to excercise a R/S, this will dash the hopes of all shareholders.
glta
18.10.10 20:49
#82
Schnöfnase
Übersetzung zum vorherigen Text
Der zuständige Redakteur/Herausgeber des Journals ,erklärte mir das die Duke Studie bereits mit einem Termin zur Veröffentlichung im Sommer 2o11 vorgesehen ist.Der Monat genau ist nicht klar er hofft jedoch im Mai oder Juni.Die Duke Universität könnte evtl mit dem Journal eine Übereinkunft treffen ,dass der Artikel eher veröffentlicht wird.(das muss natürlich von Wellstar gewollt und bezahlt werden).er hat jedoch keine Ahnung obe eine solche Anfrage seitens Wellstar statt gefunden hat.
Dann geht es weiter mit einer Einschätzung des Users über das Marktumfeld und die Chancen von Wellstar.
Für den zu erwartenden Marktanteil bzw Chancen auf diesem , muss man wissen das Thermal Imaging keine neue Technologie ist.Es gibt sie bereits seit 1982 auf dem Markt ,nach dem diese eine FDA Zulassung erhielt.Wellstar hat lediglich eine neue Möglichkeit entwickelt diese Technologie zu nutzen um zb Druckgeschwüre früh zu erkennen.Die Technologie selbst ist zb in der Brustkrebserkennung [.... ]oder in der Orthopädie im Einsatz.[...]
Anders als in der Früherkennung von Druckgeschwüren oder Tiefgewebe Verletzungen,besteht ein Sättigung mit Geräten von Großunternehmen.
Das System von Wellstar zur Druckgeschwür Erkennung ist momentan einzigartig,wenn man sich nun die Einsatzmöglichkeiten und deren Bedarf vorstellt, könnte man davon ausgehen das Wellstar die Möglichkeiten habe um kräftig zu wachsen.
[..]
Die nächsten 6-12 Monate könnten für Wellstar entscheidend sein.Wenn Wellstar es schafft das Produkt auf den Markt zu bringen kommt der Rest von allein.
Es ist einer dieser Pennystocks der ein gutes Potential hat.Die Duke Studie ist eine Rückversicherung für diese Technologie.
Das größte Risiko besteht darin das Antonio (CEO Wellstar) irgend eine idiotische Entscheidung trifft zb noch nen R/S.Dies würde das letzte vertrauen der Anleger zerstören.
So ist nicht wörtlich übersetzt und gekürzt , aber besser wie diese mist google Übersetzungeng. - Schnöf
Dann geht es weiter mit einer Einschätzung des Users über das Marktumfeld und die Chancen von Wellstar.
Für den zu erwartenden Marktanteil bzw Chancen auf diesem , muss man wissen das Thermal Imaging keine neue Technologie ist.Es gibt sie bereits seit 1982 auf dem Markt ,nach dem diese eine FDA Zulassung erhielt.Wellstar hat lediglich eine neue Möglichkeit entwickelt diese Technologie zu nutzen um zb Druckgeschwüre früh zu erkennen.Die Technologie selbst ist zb in der Brustkrebserkennung [.... ]oder in der Orthopädie im Einsatz.[...]
Anders als in der Früherkennung von Druckgeschwüren oder Tiefgewebe Verletzungen,besteht ein Sättigung mit Geräten von Großunternehmen.
Das System von Wellstar zur Druckgeschwür Erkennung ist momentan einzigartig,wenn man sich nun die Einsatzmöglichkeiten und deren Bedarf vorstellt, könnte man davon ausgehen das Wellstar die Möglichkeiten habe um kräftig zu wachsen.
[..]
Die nächsten 6-12 Monate könnten für Wellstar entscheidend sein.Wenn Wellstar es schafft das Produkt auf den Markt zu bringen kommt der Rest von allein.
Es ist einer dieser Pennystocks der ein gutes Potential hat.Die Duke Studie ist eine Rückversicherung für diese Technologie.
Das größte Risiko besteht darin das Antonio (CEO Wellstar) irgend eine idiotische Entscheidung trifft zb noch nen R/S.Dies würde das letzte vertrauen der Anleger zerstören.
So ist nicht wörtlich übersetzt und gekürzt , aber besser wie diese mist google Übersetzungeng. - Schnöf
20.10.10 19:09
#83
Menne
artikel
ich denke nicht, dass die etwas bezahlen können, um das erscheinungsdatum des artikels nach vorne zu verlegen.
allerdings wäre es für wellstar von vorteil - je eher könnte die vermarktung beginnen
bei 1,6mrd oder waren es schon 15 mrd aktien (?) erscheint ein r/s allerdings wahrscheinlich.
allerdings wäre es für wellstar von vorteil - je eher könnte die vermarktung beginnen
bei 1,6mrd oder waren es schon 15 mrd aktien (?) erscheint ein r/s allerdings wahrscheinlich.
03.11.10 11:34
#84
Menne
wie immer
- Notification that Annual Report will be submitted late (NT 10-K)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
Commission File Number 333-130295
NOTIFICATION OF LATE FILING
T Form 10-K ¨ Form 11-K ¨ Form 20-F ¨ Form 10-Q ¨ Form N-SAR
For Period Ended: July 31, 2010
¨ Transition Report on Form 10-K
¨ Transition Report on Form 20-F
¨ Transition Report on Form 10-Q
¨ Transition Report on Form N-SAR
For the Transition Period Ended: _________
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
--------------------------------------------------
PART I
REGISTRANT INFORMATION
Full name of registrant Wellstar International, Inc.
Former name if applicable
Address of principal executive office 6911 Pilliod Road
City, state and zip code Holland, Ohio, 43528
PART II
RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)
T (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
--------------------------------------------------
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.
The Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2010 cannot be filed within the prescribed time period because the Company requires additional time for compilation and review to insure adequate disclosure of certain information required to be included in the Form 10-K. The Company’s Annual Report on Form 10-K will be filed on or before the 15 th calendar day following the prescribed due date.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
John Antonio, CEO (419) 865-0069
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
T Yes ¨ No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
¨ Yes T No
If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
--------------------------------------------------
Wellstar International, Inc.
Name of Registrant as Specified in Charter.
Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 29, 2010 By: /s/ John Antonio
John Antonio
Chief Executive Officer
http://ih.advfn.com/p.php?pid=nmona&article=45016882
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
Commission File Number 333-130295
NOTIFICATION OF LATE FILING
T Form 10-K ¨ Form 11-K ¨ Form 20-F ¨ Form 10-Q ¨ Form N-SAR
For Period Ended: July 31, 2010
¨ Transition Report on Form 10-K
¨ Transition Report on Form 20-F
¨ Transition Report on Form 10-Q
¨ Transition Report on Form N-SAR
For the Transition Period Ended: _________
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
--------------------------------------------------
PART I
REGISTRANT INFORMATION
Full name of registrant Wellstar International, Inc.
Former name if applicable
Address of principal executive office 6911 Pilliod Road
City, state and zip code Holland, Ohio, 43528
PART II
RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)
T (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
--------------------------------------------------
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.
The Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2010 cannot be filed within the prescribed time period because the Company requires additional time for compilation and review to insure adequate disclosure of certain information required to be included in the Form 10-K. The Company’s Annual Report on Form 10-K will be filed on or before the 15 th calendar day following the prescribed due date.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
John Antonio, CEO (419) 865-0069
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
T Yes ¨ No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
¨ Yes T No
If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
--------------------------------------------------
Wellstar International, Inc.
Name of Registrant as Specified in Charter.
Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 29, 2010 By: /s/ John Antonio
John Antonio
Chief Executive Officer
http://ih.advfn.com/p.php?pid=nmona&article=45016882
16.11.10 11:02
#85
Menne
Annual Report (10-K)
http://ih.advfn.com/p.php?pid=nmona&article=45246937
17.11.10 16:47
#86
Schnöfnase
Meine Meinung
lasst mich meiner Worte Lügen strafen, aber wenn ich Passagen wie diese lese
Plan of Operation and Financing Needs
We are seeking financing in different amounts and up to 12 million dollars. Currently the company has exhausted its funding from it’s past agreements with JMJ Financial and is actively trying to secure financing to continue operations. If the company is successful in securing financing the company will continue to develop its camera and complete the Beta Test that is currently in operation in a Long Term Care Facility.
We presently do not have any available credit, bank financing or other external sources of liquidity. Due to our brief history and historical operating losses, our operations have not been a source of liquidity. We will need to obtain additional capital in order to expand operations and become profitable. In order to obtain capital, we may need to sell additional shares of our common stock or borrow funds from private lenders. There can be no assurance that we will be successful in obtaining additional funding.
We will still need additional capital in order to continue operations until we are able to achieve positive operating cash flow. Additional capital is being sought, but we cannot guarantee that we will be able to obtain such investments. This money would be used for the roll out of our TMI System to the long term care market and for the development and production of a new camera that will save the company money as well as be more effective in its diagnosis..
dann habe ich arge Bedenken dass diese Firma noch den nächsten Frühling erlebt ...
Plan of Operation and Financing Needs
We are seeking financing in different amounts and up to 12 million dollars. Currently the company has exhausted its funding from it’s past agreements with JMJ Financial and is actively trying to secure financing to continue operations. If the company is successful in securing financing the company will continue to develop its camera and complete the Beta Test that is currently in operation in a Long Term Care Facility.
We presently do not have any available credit, bank financing or other external sources of liquidity. Due to our brief history and historical operating losses, our operations have not been a source of liquidity. We will need to obtain additional capital in order to expand operations and become profitable. In order to obtain capital, we may need to sell additional shares of our common stock or borrow funds from private lenders. There can be no assurance that we will be successful in obtaining additional funding.
We will still need additional capital in order to continue operations until we are able to achieve positive operating cash flow. Additional capital is being sought, but we cannot guarantee that we will be able to obtain such investments. This money would be used for the roll out of our TMI System to the long term care market and for the development and production of a new camera that will save the company money as well as be more effective in its diagnosis..
dann habe ich arge Bedenken dass diese Firma noch den nächsten Frühling erlebt ...
17.11.10 16:51
#87
Schnöfnase
ahja
und was diese super Kamera betrifft , die ist somit wohl immernoch nicht Serienreif.
und wenn die eh schon keine Kohle haben dann auch nicht um die Publikation der Studie zu beschleunigen....Duke Univ. may be able to negociate with the journal to have it published sooner (of course this must be requested and funded by wellstar)....
irgendwie nen scheiss herbst was
wamu,ambac,wellstar.... more to come ^^
und wenn die eh schon keine Kohle haben dann auch nicht um die Publikation der Studie zu beschleunigen....Duke Univ. may be able to negociate with the journal to have it published sooner (of course this must be requested and funded by wellstar)....
irgendwie nen scheiss herbst was
wamu,ambac,wellstar.... more to come ^^
22.12.10 11:50
#88
Menne
10-Q 15-12-2010
- Quarterly Report (10-Q)
Date : 12/15/2010 @ 5:16PM
Source : Edgar (US Regulatory)
Stock : (WLSI)
Quote : 0.0001 0.0 (0.00%) @ 7:27AM
http://ih.advfn.com/p.php?pid=nmona&article=45673092
Date : 12/15/2010 @ 5:16PM
Source : Edgar (US Regulatory)
Stock : (WLSI)
Quote : 0.0001 0.0 (0.00%) @ 7:27AM
http://ih.advfn.com/p.php?pid=nmona&article=45673092
07.04.11 13:16
#89
Menne
Ich mach das Licht aus
Wellstar International, Inc. - FORM 8-K - April 6, 2011
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported): April 6, 2011
WELLSTAR INTERNATIONAL, INC.
(Exact name of registrant as specified in charter)
Nevada 333-130295 20-1834908
(State or Other Jurisdiction of Incorporation
or Organization) (Commission File Number) (IRS Employer Identification No.)
6911 Pilliod Road
Holland, Ohio 43528
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (419) 865-0069
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On April 6, 2011, Wellstar International, Inc. (the “Company”) announced that it has ceased operations. The Company phone number has been disconnected and the lease for the Holland, Ohio facility has been terminated.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WELLSTAR INTERNATIONAL, INC.
Date: April 6, 2011 By: /s/ John Antonio
Name: John Antonio
Title: CEO
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported): April 6, 2011
WELLSTAR INTERNATIONAL, INC.
(Exact name of registrant as specified in charter)
Nevada 333-130295 20-1834908
(State or Other Jurisdiction of Incorporation
or Organization) (Commission File Number) (IRS Employer Identification No.)
6911 Pilliod Road
Holland, Ohio 43528
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (419) 865-0069
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On April 6, 2011, Wellstar International, Inc. (the “Company”) announced that it has ceased operations. The Company phone number has been disconnected and the lease for the Holland, Ohio facility has been terminated.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WELLSTAR INTERNATIONAL, INC.
Date: April 6, 2011 By: /s/ John Antonio
Name: John Antonio
Title: CEO